The deal, which will combined Immunologix’ Ab production capabilities with GenScript’s range of early development and scale-up services, will focus on providing drug firms with everything from discovery to trial stage support.
Nick Yan, GenScript VP, said: “Jointly, we can offer one-stop solutions and complete portfolios to our clients for all their needs in human therapeutic antibody from target identification to clinic candidates cost-effectively and time-efficiently.”
The global antibody therapeutics market, worth around $27.4bn in 2008, will generate revenue of some $67.6bn by 2015 according to recent analysis by GBI Research.
This growth is likely to attract the attention of a drug industry keen to maintain profitability and, in turn, generate business for the contract research organisations that serve this highly specialised part of the drug industry.